Christina Tsai, PhDSenior Scientist at IGM Biosciences
Christina Tsai is a senior scientist in the Cell Line Development Group in IGM Biosciences. Her work in IGM is focused on CHO cell line development and particularly in the proteomic and genomic identification of cell lines for the production of intact IgM molecules. She has 10+ years of experience in process development in various kinds of cell lines, including CHO, HEK, Pichia, etc. Prior to IGM, she works on cell line development and IgG molecule characterization in Hengenix Biotech and Samsung Biologics. In addition, she founded a microbiome company, EpiBiome, which was acquired by Locus Biosciences.